High‐grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging. Issue 11 (15th June 2016)

• Record Type: Journal Article
• Authors: Lou, Sha; Balluff, Benjamin; de Graaff, Marieke A.; Cleven, Arjen H.G.; Briaire ‐ de Bruijn, Inge; Bovée, Judith V.M.G.; McDonnell, Liam A.
• Other Names: Clench Malcolm R. guestEditor.
• Is Part Of: Proteomics. Volume 16:Issue 11/12(2016)
• Page Start: 1802
• Page End: 1813
• Publication Date: 2016-06-15
• Subjects: Biomarker discovery -- Biomedicine -- Intratumor heterogeneity -- Mass spectrometry imaging -- Soft tissue sarcoma; Proteins -- Separation -- Periodicals; Bioinformatics -- Periodicals; Proteomics -- Periodicals; Genomes -- Periodicals; Molecular genetics -- Periodicals; 572.605
• DOI: 10.1002/pmic.201500514
• Languages: English
• ISSNs: 1615-9853

Abstract

Abstract : The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high‐grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDI‐MSI of proteins to distinguish between high‐grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) ( N total = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors ( p ≤ 0.05), amongst them acyl‐CoA‐binding protein ( m/z 11 162), macrophage migration inhibitory factor ( m/z 12 350), thioredoxin ( m/z 11 608) and galectin‐1 ( m/z 14 633) were assigned. Another nine protein signals were found to be associated with overall survival ( p ≤ 0.05), including proteasome activator complex subunit 1 ( m/z 9753), indicative for non‐OS patients with poor survival; and two histone H4 variants ( m/z 11 314 and 11 355), indicative of poor survival for LMS patients.